Acorda Therapeutics, Inc. (NASDAQ:ACOR) headquartered in Ardsley, will host a conference call for the investment community to discuss the 3Q20 financial results on 3rd November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.acorda.com
Earnings Expectation
Acorda Therapeutics, Inc. is reporting third quarter earnings results on Tuesday 3rd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.31 per share from $ 29.29 million in revenue. For the full year, analysts predict revenues of $ 119.34 million, while looking forward to loss of $ 1.64 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 130.00 million ~ $ 160.00 million
Click Here For More Historical Outlooks Of Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
